ZNTL Zentalis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZNTL

Price (delayed)

$3.895

Market cap

$277.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.73

Enterprise value

$277.36M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 14

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of ...

Highlights
ZNTL's gross profit has soared by 100% YoY
The revenue has surged by 100% year-on-year
ZNTL's equity is down by 38% YoY and by 16% from the previous quarter
Zentalis Pharmaceuticals's quick ratio has decreased by 11% from the previous quarter and by 10% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zentalis.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ZNTL

ZNTL stock price

How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
4.7%
1 week
-3.83%
1 month
-2.63%
1 year
159.67%
YTD
188.52%
QTD
66.45%

Financial performance

How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$145.04M
Net income
-$124.13M
Gross margin
N/A
Net margin
N/A
ZNTL's gross profit has soared by 100% YoY
The revenue has surged by 100% year-on-year
The operating income has grown by 48% YoY and by 5% from the previous quarter
Zentalis Pharmaceuticals's net income has increased by 45% YoY and by 9% from the previous quarter

Price vs fundamentals

How does ZNTL's price correlate with its fundamentals

Growth

What is Zentalis Pharmaceuticals's growth rate over time

Valuation

What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Zentalis Pharmaceuticals's EPS has increased by 45% YoY and by 9% from the previous quarter
The P/B is 188% more than the last 4 quarters average of 0.5 but 54% less than the 5-year quarterly average of 3.1
ZNTL's equity is down by 38% YoY and by 16% from the previous quarter
The revenue has surged by 100% year-on-year

Efficiency

How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC is up by 21% year-on-year
The ROA is up by 20% year-on-year
The ROE rose by 18% year-on-year

Dividends

What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZNTL.

Financial health

How did Zentalis Pharmaceuticals financials performed over time
The total assets has contracted by 34% YoY and by 12% from the previous quarter
The total liabilities has declined by 21% year-on-year and by 3.3% since the previous quarter
The company's debt is 81% lower than its equity
The debt to equity has grown by 46% year-on-year and by 12% since the previous quarter
ZNTL's equity is down by 38% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.